Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing
Bonerge's 12-week, quadruple-blind study evaluates how Urolithin A and Fisetin influence sleep via metabolic and epigenetic biomarkers.
Share
This randomized, quadruple-blind (participants, healthcare providers, researchers, assessors), placebo-controlled study will enroll over 80 participants aged 45-70. They will be divided into four groups: Urolithin A alone, Fisetin alone, Urolithin A + Fisetin combination, and placebo control. The 12-week intervention represents the first systematic evaluation of Urolithin A's potential to resynchronize circadian rhythms and mitigate age-related sleep disturbances.
Key Study Design Features:
Inclusion Criteria: Targets subclinical individuals with impaired sleep quality (PSQI score >5) but no pathological diagnosis, excluding those dependent on caffeine/alcohol.
Multidimensional Assessment:
Subjective: Sleep quality scores, chronotype questionnaire, daytime dysfunction scales.
Objective: Continuous actigraphy monitoring, polysomnography (PSG) analysis.
Biomarkers: NAD+ levels, DNA methylation age, inflammatory markers (IL-6, TNF-α), cortisol rhythm, circadian proteins (BMAL1, PER2), insulin resistance (HOMA-IR), immunoglobulin levels.
"We aim to uncover the causal link between sleep disorders and ageing using epigenetic clocks and metabolic markers, beyond just tracking sleep duration," stated Professor Chen, the lead investigator. "Combining Urolithin A, a circadian regulator, with the senolytic Fisetin explores synergy for novel solutions, like menopausal sleep issues."
Scientific Commitment: Building a Health Ecosystem
As a leading high-quality ingredient producer, Bonerge's R&D follows a pipeline of 'ingredient science, mechanistic research, clinical translation'. The company is actively seeking global clinical partners from academia and industry to explore Urolithin A's potential in sleep health and cellular ageing intervention.
Amidst the anti-ageing industry's shift from consumerism to scientific rigor, Bonerge positions Urolithin A not just as a standalone ingredient, but as a catalyst for evidence-based solutions. Focused on core mechanisms like cellular senescence, Bonerge develops innovative ingredients targeting cellular health, forming a robust "health ecosystem." Key components include:
Fisetin: Potent senolytic selectively clearing senescent cells and reducing their formation, retarding aging in skin, ovarian, and neural tissues.
Urolithin A: Regulates circadian rhythms, boosts endogenous NAD+ synthesis, enhances cellular repair, and improves sleep quality and reproductive health.
L-Ergothioneine: Unique antioxidant with a dedicated transporter (OCTN1), accumulating in high-stress tissues to neutralize ROS, protecting DNA and telomeres.
PQQ Disodium: Activates the PGC-1α/PPARγ pathway, driving mitochondrial DNA replication and biogenesis.
S - Equol: Natural, non-steroidal estrogenic metabolite with high affinity for ERβ, offering a safer alternative for menopause health.
About Bonerge
Bonerge firmly contends that the future of anti-ageing hinges on evidence-based solutions. These solutions are grounded in well-defined biological mechanisms, supported by robust scientific data, and tailored to precise applications, ultimately delivering comprehensive, science-validated health benefits. For more detailed information about our clinical findings, discover more about us at http://www.bonerge.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENSai™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials. The platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. Share 'ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars,' said Dr. Jennifer Bath, President & CEO, IPA. 'With LENSai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules.' Late‑stage ADA failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. Yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑MHC II binding across a few dozen HLA alleles—leaving large swaths of immune diversity untested and immunogenic 'self/non‑self' checks largely unaddressed. LENSai's HYFT‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. It evaluates nearly 900 HLA variants and performs a whole‑proteome 'humanness' scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. By revealing design‑level fixes before expensive animal studies or repeat GMP production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. Study Highlights 217 marketed and clinical-stage antibodies analyzed – the largest public ADA dataset to predict immunogenicity risk – the largest public ADA dataset to predict immunogenicity risk Single composite score tracks clinical reality – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92. – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92. Alignment-free, HYFT-powered engine – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. Detailed amino acid and epitope-level immunogenicity 'self' scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays. Read the full case study: [link] About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Forward-Looking Statements This press release contains forward looking statements within the meaning of applicable United States and Canadian securities laws. Forward looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' 'potential,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. Examples include statements regarding the projected performance, scalability, and market adoption of the Company's LENSai™ Immunogenicity Screening; the ability of its HYFT® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ADA prediction on biopharma R&D efficiency; and the Company's broader scientific, commercial, and capital markets objectives. Forward looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results could differ materially from those expressed or implied because of factors beyond the Company's control, including the pace of scientific and technological innovation in AI driven drug discovery, the accuracy and regulatory acceptance of in-silico ADA risk screening, competitive shifts as the industry transitions away from MS dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. Additional information about these and other risks and uncertainties is set out in the Company's Annual Report on Form 20F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at If any of these risks materialize, the Company's actual results, performance, or achievements could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on forward looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.
Business Wire
2 hours ago
- Business Wire
Geneoscopy's New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening
ST. LOUIS--(BUSINESS WIRE)-- Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, received FDA approval to streamline the stool collection process for ColoSense®, its RNA-based colorectal cancer (CRC) screening test. The newly approved collection kit no longer requires patients to separate their sample into multiple containers. This improves ease of use and reduces barriers to at-home screening, 1 while maintaining clinical performance. 'We've taken a critical step toward improving the at-home colorectal cancer screening experience by removing one of the most burdensome aspects for patients—the scraping of stool,' said Dr. Erica Barnell, Chief Medical & Science Officer of Geneoscopy. 'The new collection kit simplifies the process for collecting a patient's stool sample. By eliminating the most confusing and undesirable step, we believe ColoSense will drive higher adherence and better outcomes.' ColoSense is indicated for individuals aged 45 and older who are at average risk for CRC. It uses advanced RNA technology to detect biomarkers associated with CRC and advanced adenomas (AA)—precancerous growths that can develop into cancer if left untreated. As the only FDA-approved RNA-based test for CRC screening, ColoSense demonstrated 93% sensitivity for CRC and 45% sensitivity for AA in average-risk individuals. Among average-risk individuals aged 45 to 49, where CRC incidence is on the rise, the test demonstrated 100% sensitivity for CRC and 44% sensitivity for AA.* Despite the availability of multiple screening options, an estimated 44 million people aged 45-75 remain unscreened for CRC. 2 To help address a common barrier to stool-based screening, the updated ColoSense collection kit removes the need to scrape the sample. This improvement is expected to increase patient compliance, lower the rate of collection errors, and reduce the frequency of invalid samples. This ease of use can translate into fewer missed screenings and a greater overall impact on population health. 'To exceed 80% compliance for colorectal cancer screening, the patient experience for stool-based screening must be improved,' said Andrew Barnell, Chief Executive Officer of Geneoscopy. 'The new ColoSense test does that, offering patients everything they like about at-home, high-sensitivity screening, but now, with an easier collection process.' ColoSense is included in National Comprehensive Cancer Network (NCCN) guidelines, based on an evaluation of the strength of its clinical evidence and the robust science behind the technology. The test will be available through Geneoscopy's strategic collaboration with Labcorp, expanding access for providers and patients across the United States. ColoSense represents a significant advancement in noninvasive stool testing options, reinforcing the importance of accessible tools that help reach individuals who are less likely to undergo colonoscopy. About ColoSense ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults aged 45 years or older who are at the typical average risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. Results from Geneoscopy's pivotal CRC-PREVENT trial were published in The Journal of the American Medical Association (JAMA). For more information, visit About Geneoscopy, Inc. Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit and follow the company on LinkedIn. References Luque JS, Wallace K, Blankenship BF, et al. Formative Research on Knowledge and Preferences for Stool-based Tests compared to Colonoscopy: What Patients and Providers Think. J Community Health. 2018;43(6):1085-1092. doi:10.1007/s10900-018-0525-x Hyams T, Mueller N, Curbow B, et al. Screening for colorectal cancer in people ages 45–49: research gaps, challenges and future directions for research and practice, Transl. Behav. Med, Volume 12, Issue 2, Feb 2022, Pages 198–202. *ColoSense identified 5/5 colorectal cancers and 37/84 advanced adenomas.
Business Wire
2 hours ago
- Business Wire
Heritage Group Closes on $370 Million Fourth Fund
NASHVILLE, Tenn.--(BUSINESS WIRE)--Heritage Group, a healthcare-focused private equity firm, today announced the final closing of Heritage Healthcare Innovation Fund IV ('Fund IV' or the 'Fund') at over $370 million, marking another significant milestone in the firm's continued growth. Fund IV builds on Heritage Group's successful strategy of making minority and majority investments in solution-oriented, high-growth healthcare services and technology businesses that address the industry's most pressing challenges. Heritage Group's deep strategic engagement model ensures that their health system and payer limited partners add value throughout the investment lifecycle—from sourcing and diligence to portfolio company growth and commercialization. Share 'We are grateful for the continued support from our longtime investors and excited to welcome several new limited partners to Fund IV,' said Jesse Bland, Partner at Heritage Group. 'Their confidence reflects the strength of our strategic model and our ability to identify and scale businesses across some of the highest growth subsectors of the healthcare ecosystem.' Heritage is backed by leading healthcare organizations, including major health systems operating more than 800 hospitals, payers insuring over 75 million lives, and other key healthcare service providers. 'Our strategic investors aren't just capital providers—they're true partners in how we source, evaluate, and grow businesses,' said Bryan Bui, Partner at Heritage Group. 'We work hard to maintain a two-way dialogue with our limited partners, ensuring they have early and direct access to emerging innovation while also bringing their insights into every stage of our investment process.' Heritage Group's deep strategic engagement model ensures that their health system and payer limited partners add value throughout the investment lifecycle—from sourcing and diligence to portfolio company growth and commercialization. This strategic investment approach provides proprietary insights and real-time market intelligence, enabling Heritage to take a thematic approach to investing by targeting segments of the healthcare industry positioned for meaningful and sustained growth. 'Heritage enables us to engage directly with some of the most forward-thinking healthcare companies in the market,' said Tim Hingtgen, CEO of Community Health Systems. 'Their ability to surface emerging trends early, connect us with innovative solutions, and create meaningful opportunities for strategic collaboration across the ecosystem makes them a uniquely valuable partner.' Heritage Group's portfolio spans several high-impact themes including the shift to lower-cost sites of care, such as ambulatory infusion (TwelveStone) and home-based care (Upward Health); enabling value-based care through companies like Curana Health and Wellvana; supporting health systems through outsourced clinical services (Equum, a leader in teleICU and telenursing, and Shearwater Health, a clinical process outsourcer); and expanding access to care via platforms such as MDLIVE and Connections Health Solutions. 'Heritage has been an invaluable partner to our team—delivering strategic value well beyond capital,' said David Siegel, CEO of Nationwide Medical, a Heritage Group portfolio company. 'Their deep understanding of the healthcare landscape, collaborative approach, and strategic connectivity have helped us accelerate growth and expand our impact in meaningful ways.' About Heritage Group Heritage Group is a Nashville, Tennessee-based, healthcare-focused private equity firm with more than 40 years of experience financing and operating healthcare companies. Heritage has over $1 billion of assets under management and seeks to make majority and minority investments in high-growth healthcare services and healthcare technology businesses that address the challenges of the U.S. healthcare system. The firm's limited partners include some of the leading healthcare organizations in the nation, including large provider systems, payers, and healthcare service providers, which collectively operate over 800 hospitals and insure more than 75 million lives. For more information, visit
